ABS Direct Equity Fund’s Cogent Biosciences COGT Stock Holding History

ABS Direct Equity Fund’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$173K	Buy	+4,700	New	+$174K	0.13%	88

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

ABS Direct Equity Fund's COGT Position: Q1 2026 in Review

ABS Direct Equity Fund opened a new position in Cogent Biosciences (COGT) in Q1 2026: 4,700 shares worth $173K. The stake represents 0.13% of the portfolio and ranks #88 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

ABS Direct Equity Fund held 4,700 shares of Cogent Biosciences worth $173K as of Q1 2026.
Cogent Biosciences was a new ABS Direct Equity Fund position in Q1 2026.
Cogent Biosciences made up 0.13% of ABS Direct Equity Fund's portfolio in Q1 2026, its #88 holding.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.